Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma

Summary

The aim of this study is to analyze the efficacy of O-ESHAP treatment for Hodgkin's lymphome patients that have a first line chemotherapy treatment failure due to refractoriness, partial response or relapsed. In the same way, mortality, global survival and free-progression survival after O-ESHAP treatment and TAPH will also analyzed.

Timeline

Start

2010-07

Primary completion

2013-09

Completion

2015-05

Drugs

Indications